Quanterix Corp
$ 7.48
8.56%
03 Dec - close price
- Market Cap 349,397,000 USD
- Current Price $ 7.48
- High / Low $ 7.50 / 6.85
- Stock P/E N/A
- Book Value 6.74
- EPS -2.54
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.29 %
- 52 Week High 12.41
- 52 Week Low 4.05
About
Quanterix Corporation is a pioneering life sciences innovator headquartered in Billerica, Massachusetts, dedicated to advancing precision health through its groundbreaking digital immunoassay platforms. The company specializes in ultra-sensitive biomarker detection, significantly enhancing research and diagnostics across various therapeutic areas and facilitating advancements in disease comprehension and personalized medicine. With a robust global footprint spanning North America, Europe, the Middle East, Africa, and Asia Pacific, Quanterix is strategically positioned as a leader in the healthcare and diagnostics arena, committed to transforming patient outcomes and propelling innovation within the life sciences industry.
Analyst Target Price
$6.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-02-29 | 2023-11-06 | 2023-08-07 | 2023-05-09 | 2023-03-06 |
| Reported EPS | -0.73 | -0.77 | -0.53 | -0.3 | -0.2186 | -0.25 | -0.26 | -0.33 | -0.21 | -0.16 | -0.16 | -0.5 |
| Estimated EPS | -0.4648 | -0.43 | -0.432 | -0.254 | -0.2443 | -0.27 | -0.31 | -0.32 | -0.37 | -0.38 | -0.38 | -0.47 |
| Surprise | -0.2652 | -0.34 | -0.098 | -0.046 | 0.0257 | 0.02 | 0.05 | -0.01 | 0.16 | 0.22 | 0.22 | -0.03 |
| Surprise Percentage | -57.0568% | -79.0698% | -22.6852% | -18.1102% | 10.5199% | 7.4074% | 16.129% | -3.125% | 43.2432% | 57.8947% | 57.8947% | -6.383% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4247 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTRX
2025-10-17 06:45:32
Leerink Partnrs has issued an earnings forecast for Quanterix (NASDAQ: QTRX) ahead of its Q2 earnings report. Other brokerages, including Canaccord Genuity Group, have also recently commented on Quanterix, with institutional investors significantly increasing their holdings in the company. The article also provides an overview of Quanterix Corporation's business, which involves the development and marketing of digital immunoassay platforms.
2023-10-04 15:30:18
A retrospective study compared total-tau protein serum concentrations in migraine patients and healthy controls, finding elevated levels in both episodic and chronic migraine patients. These elevated serum tau protein levels suggest a potential new target for migraine research. The study also noted that other cell damage proteins (NfL, GFAP, and UCH-L1) did not show significant differences between the groups.
2023-08-09 15:30:18
Quanterix Corporation announced the appointment of Vandana Sriram, CPA, as its new Chief Financial Officer, effective August 21, 2023. Sriram brings over 20 years of experience in financial strategy and transformation, previously serving as Senior Vice President of Global Finance at Azenta Life Sciences and in senior roles at GE Aviation. She replaces Michael Doyle, who will transition to an Executive Director role focused on strategic growth programs until his retirement in March 2024.
2023-01-09 15:30:18
Quanterix Corporation has launched a new Laboratory Developed Test (LDT) to measure neurofilament light chain (NfL) in serum, aiming to aid in the evaluation of individuals for neurodegenerative conditions. This CLIA-validated blood test expands access to an important "brain health" biomarker and is expected to power future therapeutic trials and advance clinical care by enabling earlier and more accessible detection of neurological damage. The Simoa NfL LDT will be offered through Quanterix’s Accelerator Laboratory.
2022-11-08 18:16:47
Quanterix Corporation reported its Q3 2022 operating results, with revenue of $26.6M, flat year-over-year when excluding prior year NIH RADx funding, and up 13% sequentially. The company is advancing its Bio-Hermes trial and Alzheimer's diagnostic development while also undertaking a comprehensive restructuring that incurred significant charges. Despite financial impacts from inventory reserves and restructuring, Quanterix noted quarter-over-quarter improvements in revenue and gross margin, driven by expense reductions and product mix shift.
2022-04-22 18:16:47
Quanterix received FDA breakthrough device designation for its Simoa neurofilament light chain (NfL) plasma test, designed as a prognostic aid for multiple sclerosis (MS). This diagnostic tool helps assess the risk of disease activity in patients with relapsing-remitting MS (RRMS) and informs therapeutic approaches, following a large-scale international study affirming its effectiveness. The company plans to work with the FDA to advance the test toward regulatory approval.
